Piper Sandler Maintains Neutral on Travere Therapeutics, Raises Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Nicole Gabreski has maintained a Neutral rating on Travere Therapeutics (NASDAQ:TVTX) and increased the price target from $10 to $11.
January 18, 2024 | 7:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler has maintained a Neutral rating on Travere Therapeutics and raised the price target from $10 to $11.
The increase in price target by Piper Sandler suggests a positive outlook on the stock's value, which could lead to a short-term increase in investor confidence and potentially a rise in the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100